"id","name","label","uuid:ID","instanceType","rationale","description"
"StudyDesign_1","Study Design 1","","acd83853-f324-46a0-b6cc-d74c2dbe656f","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study"
